83 related articles for article (PubMed ID: 1567158)
41. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
42. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ
Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635
[TBL] [Abstract][Full Text] [Related]
43. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
Rönnblom LE; Alm GV; Oberg KE
Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
[TBL] [Abstract][Full Text] [Related]
44. [2 year interferon therapy of metastatic carcinoid tumor].
von Scheidt W; Böhm M; Huber I; Habersetzer R; Jacob K; Markl A; Autenrieth G
Klin Wochenschr; 1990 Feb; 68(4):241-6. PubMed ID: 2107357
[TBL] [Abstract][Full Text] [Related]
45. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.
Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N
Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678
[TBL] [Abstract][Full Text] [Related]
46. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
Joensuu H; Kätkä K; Kujari H
Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
[TBL] [Abstract][Full Text] [Related]
47. Interferon-alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion.
Ahrén B
Eur J Surg; 1993 Apr; 159(4):209-12. PubMed ID: 8102540
[TBL] [Abstract][Full Text] [Related]
48. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.
Schöber C; Schmoll E; Schmoll HJ; Poliwoda H; Schuppert F; Stahl M; Bokemeyer C; Wilke H; Weiss J
Eur J Cancer; 1992; 28A(10):1664-6. PubMed ID: 1382494
[TBL] [Abstract][Full Text] [Related]
49. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
50. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon.
Moertel CG; Rubin J; Kvols LK
J Clin Oncol; 1989 Jul; 7(7):865-8. PubMed ID: 2738623
[TBL] [Abstract][Full Text] [Related]
51. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon.
Kälkner KM; Rönnblom L; Karlsson Parra AK; Bengtsson M; Olsson Y; Oberg K
QJM; 1998 Jun; 91(6):393-9. PubMed ID: 9709457
[TBL] [Abstract][Full Text] [Related]
52. Thyrotoxicosis after interferon-alpha therapy.
Csaki AC; Blum M
Thyroid; 2000 Jan; 10(1):101. PubMed ID: 10691322
[No Abstract] [Full Text] [Related]
53. Autoimmunity and antibodies to interferons in patients with carcinoid tumors--clinical consequences.
Oberg KE
J Interferon Res; 1994 Aug; 14(4):215-6. PubMed ID: 7822879
[No Abstract] [Full Text] [Related]
54. Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells.
Alvarez MC; Macías AA; Saurez MG; Fernández ML; Lage DA
Cancer Biol Ther; 2007 Jun; 6(6):853-5. PubMed ID: 17611391
[TBL] [Abstract][Full Text] [Related]
55. The management of carcinoid tumours.
Halford S; Waxman J
QJM; 1998 Dec; 91(12):795-8. PubMed ID: 10024944
[No Abstract] [Full Text] [Related]
56. Influence of interferon and radiation on serotonin content in primary carcinoid cell cultures.
Jacobsen MB; Bratlie J; Reitan JB; Hellesnes J; Hanssen LE
Acta Oncol; 1993; 32(2):239-43. PubMed ID: 8323763
[TBL] [Abstract][Full Text] [Related]
57. Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours.
Pape UF; Wiedenmann B
Cancer Treat Rev; 2003 Dec; 29(6):565-9. PubMed ID: 14585268
[No Abstract] [Full Text] [Related]
58. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
59. Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
Ahren B; Engman K; Lindblom A
Anticancer Res; 1992; 12(1):129-33. PubMed ID: 1567158
[TBL] [Abstract][Full Text] [Related]
60. Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
Ahren B; Engman K; Lindblom A
Anticancer Res; 1992; 12(3):881-4. PubMed ID: 1622146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
